Brief: Ultimovacs Says Primary And Secondary Endpoints Of Initium Study Not Met

Zelluna ASA

07/03/2024 06:07

March 7 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * REG-ULTIMOVACS ANNOUNCES TOPLINE RESULTS FROM INITIUM
STUDY
EVALUATING UV1 VACCINATION ADDED TO IPILIMUMAB AND NIVOLUMAB IN
PATIENTS WITH UNRESECTABLE OR METASTATIC MALIGNANT MELANOMA
    * UV1 MAINTAINED ITS POSITIVE SAFETY PROFILE WITH SIMILAR
SAFETY
AND TOLERABILITY AS OBSERVED IN CONTROL ARM
    * TRIAL DID NOT MEET PRIMARY ENDPOINT OF PROLONGING
PROGRESSION-FREE SURVIVAL (PFS)
    * MEDIAN PFS WAS NOT REACHED IN EITHER ARM
    * ULTIMOVACS-EVALUATION OF SECONDARY ENDPOINTS DID NOT SHOW
DIFFERENCE IN OVERALL SURVIVAL AND OBJECTIVE RESPONSE RATE
BETWEEN TREATMENT AND CONTROL ARMS
    * CASH PRESERVATION INITIATIVES WILL BE IMPLEMENTED TO
ENSURE THAT
AVAILABLE FINANCIAL RESOURCES WILL SUSTAIN COMPANY INTO 2025

Source text for Eikon:  ID:nGNE4D9KQK 
Further company coverage:  ULTI.OL 

 ((Reuters.Briefs@thomsonreuters.com;))